Home / Market News / $ALHC
benzinga Corporate Catalyst Impact 65/100 ● negative

Keybanc Maintains Overweight on Alignment Healthcare, Lowers Price Target to $12

Oct 9, 2026, 1:04 PM UTC · Primary ticker $ALHC

Keybanc analyst Matthew Gillmor maintained an Overweight rating on Alignment Healthcare (ALHC) but significantly lowered its price target from $28 to $12. This substantial price target reduction, despite the maintained rating, indicates a revised outlook on the company's valuation and future growth prospects.

Keybanc's decision to maintain an 'Overweight' rating on Alignment Healthcare (ALHC) while drastically cutting its price target from $28 to $12 suggests a complex view. It implies that while the analyst still sees long-term potential or relative outperformance within its sector, the immediate valuation has been significantly re-evaluated downwards. This could be due to revised financial models, competitive pressures, or a more cautious outlook on the company's ability to achieve previous growth projections. For traders, this is a negative signal in the short term, as the price target cut will likely put downward pressure on the stock, despite the maintained rating. Long-term investors might view this as a potential buying opportunity if they believe the new price target is overly conservative, but the immediate implication is a re-rating of the stock's value.

$ALHC negative Price target lowered significantly
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.